PASG News and Press, Passage Bio Inc. From 02/19/21

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of di...

The following slide deck was published by Passage Bio, Inc. in conjunction with this event. For further details see: Passage Bio (PASG) Presents At J.P. Morgan 39th Annual Healthcare Conference - Slideshow

The FDA clears Passage Bio's (PASG) investigational new drug ((IND)) application for PBKR03, an adeno-associated virus ((AAV))-delivery gene therapy being studied for the treatment of early infantile Krabbe disease.Krabbe disease is a rare lysosomal storage disease that most often presents ea...

- Phase 1/2 trial expected to commence in first half of 2021 - Company has three INDs cleared for rare monogenic CNS disorders PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative t...

The FDA has signed off investigational new drug application for Passage Bio's ([[PASG]] -0.9%) PBFT02, an adeno-associated virus-delivery gene therapy for the treatment of patients with Frontotemporal Dementia ((FTD)), a form of early onset dementia, with granulin mutation...

– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Dise...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The Dow Jones and S&P 500 indexes fell slightly on Friday but clawed back from their worst losses, while the Nasdaq edged higher to another record clos...

Shares of Passage Bio (NASDAQ: PASG) were down by 13.7% at 2:20 p.m. EST after the biotech disclosed pricing of its secondary offering of 7 million shares at $22 per share. The gene therapy company will gross $154 million from the stock sale, although the capital raise could increas...

Gainers: AzurRx BioPharma (AZRX) +59%.Climate Change Crisis Real Impact I Acquisition (CLII) +59%.GameStop (GME) +55%.Adamis Pharmaceuticals (ADMP) +41%.111 (YI) +41%.Asia Pacific Wire & Cable (APWC) +37%.Polar Power (POLA) +35%.Electro-Sensors (ELSE) +31%.Mmtec (MTC) +28%.MingZ...

Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenu...